These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 18037416

  • 1. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
    Leitch HA.
    Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
    [Abstract] [Full Text] [Related]

  • 2. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
    Gattermann N.
    Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
    [Abstract] [Full Text] [Related]

  • 3. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
    Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P, GFM (Groupe Francophone des Myélodysplasies).
    Leuk Res; 2010 Jul; 34(7):864-70. PubMed ID: 20129667
    [Abstract] [Full Text] [Related]

  • 4. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy.
    Leitch HA, Chase JM, Goodman TA, Ezzat H, Rollins MD, Wong DH, Badawi M, Leger CS, Ramadan KM, Barnett MJ, Foltz LM, Vickars LM.
    Hematol Oncol; 2010 Mar; 28(1):40-8. PubMed ID: 19557769
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
    Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.
    Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
    [Abstract] [Full Text] [Related]

  • 7. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes.
    Malcovati L.
    Leuk Res; 2007 Dec; 31 Suppl 3():S2-6. PubMed ID: 18037415
    [Abstract] [Full Text] [Related]

  • 8. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [Abstract] [Full Text] [Related]

  • 9. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.
    Chacko J, Pennell DJ, Tanner MA, Hamblin TJ, Wonke B, Levy T, Thomas PW, Killick SB.
    Br J Haematol; 2007 Sep; 138(5):587-93. PubMed ID: 17610536
    [Abstract] [Full Text] [Related]

  • 10. Iron chelation therapy in myelodysplastic syndrome - Cui bono?
    Tefferi A, Stone RM.
    Leukemia; 2009 Aug; 23(8):1373. PubMed ID: 19672273
    [No Abstract] [Full Text] [Related]

  • 11. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
    Leitch HA, Parmar A, Wells RA, Chodirker L, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, Sabloff M, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Kew A, Shamy A, Elemary M, Lenis M, Mamedov A, Ivo J, Francis J, Zhang L, Buckstein R.
    Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
    [Abstract] [Full Text] [Related]

  • 12. Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines.
    Mittelman M, Lugassy G, Merkel D, Tamary H, Sarid N, Rachmilewitz E, Hershko C, MDS Israel Group, Israel Society of Hematology.
    Isr Med Assoc J; 2008 May; 10(5):374-6. PubMed ID: 18605364
    [No Abstract] [Full Text] [Related]

  • 13. Iron chelation therapy for patients with myelodysplastic syndrome.
    Yeh SP, Yang YS, Yao CY, Peng CT.
    Hemoglobin; 2009 May; 33(5):339-45. PubMed ID: 19814680
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis.
    Leitch HA, Chan C, Leger CS, Foltz LM, Ramadan KM, Vickars LM.
    Leuk Res; 2012 Nov; 36(11):1380-6. PubMed ID: 22921191
    [Abstract] [Full Text] [Related]

  • 16. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
    Dreyfus F.
    Blood Rev; 2008 Dec; 22 Suppl 2():S29-34. PubMed ID: 19059054
    [Abstract] [Full Text] [Related]

  • 17. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S.
    Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
    [Abstract] [Full Text] [Related]

  • 18. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
    Shammo JM, Komrokji RS.
    Expert Rev Hematol; 2018 Jul; 11(7):577-586. PubMed ID: 29902097
    [Abstract] [Full Text] [Related]

  • 19. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
    Maurillo L, Breccia M, Buccisano F, Voso MT, Niscola P, Trapè G, Tatarelli C, D'Addosio A, Latagliata R, Fenu S, Piccioni AL, Fragasso A, Aloe Spiriti MA, Refrigeri M, Criscuolo M, Musto P, Venditti A.
    Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
    [Abstract] [Full Text] [Related]

  • 20. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy.
    Wong CAC, Wong SAY, Leitch HA.
    Leuk Res; 2018 Apr; 67():75-81. PubMed ID: 29477023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.